

# Thomas J Hwang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7524095/publications.pdf>

Version: 2024-02-01

80  
papers

1,921  
citations

331670

21  
h-index

289244

40  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D. <i>JAMA Oncology</i> , 2022, 8, 155.	7.1	5
2	New Treatments for Migraine—Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe. <i>JAMA Internal Medicine</i> , 2022, 182, 101.	5.1	3
3	New EU regulation on health technology assessment of cancer medicines. <i>Lancet Oncology</i> , The, 2022, 23, e58.	10.7	4
4	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. <i>Lancet Oncology</i> , The, 2022, 23, 514-520.	10.7	22
5	Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019. <i>JAMA Network Open</i> , 2022, 5, e226479.	5.9	8
6	Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010–2018. <i>Journal of General Internal Medicine</i> , 2022, , .	2.6	5
7	Coverage of New Drugs in Medicare Part D. <i>Milbank Quarterly</i> , 2022, 100, 562-588.	4.4	3
8	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. <i>JCO Oncology Practice</i> , 2022, 18, e1522-e1532.	2.9	16
9	Paying for Prescription Drugs in the New Administration. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 819.	7.4	9
10	Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid. <i>Proceedings - Academy of Management</i> , 2021, 2021, 10106.	0.1	1
11	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. <i>JAMA Oncology</i> , 2021, 7, e212026.	7.1	46
12	European Medicines Agency’s Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 541-552.	4.7	9
13	Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 224-228.	6.3	16
14	Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis. <i>Health Affairs</i> , 2020, 39, 1799-1805.	5.2	17
15	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. <i>BMJ</i> , The, 2020, 371, m3434.	6.0	56
16	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	4.1	19
17	Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). <i>JAMA Pediatrics</i> , 2020, 174, 825.	6.2	28
18	Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. <i>Lancet Oncology</i> , The, 2020, 21, 664-670.	10.7	126

#	ARTICLE	IF	CITATIONS
19	Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.. Journal of Clinical Oncology, 2020, 38, 7052-7052.	1.6	0
20	Launch prices and price developments of cancer drugs in the United States and Europe.. Journal of Clinical Oncology, 2020, 38, 2006-2006.	1.6	0
21	Pivotal trial endpoints and prices of cancer drugs in the US and Europe.. Journal of Clinical Oncology, 2020, 38, 2077-2077.	1.6	0
22	Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. JAMA - Journal of the American Medical Association, 2019, 322, 267.	7.4	21
23	Increasing the Transparency of FDA Review to Enhance the Innovation Process. , 2019, , 185-195.		0
24	Prescription Opioid Epidemic and Trends in the Clinical Development of New Pain Medications. Mayo Clinic Proceedings, 2019, 94, 2437-2443.	3.0	5
25	Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Affairs, 2019, 38, 313-319.	5.2	19
26	Pre-market development times for biologic versus small-molecule drugs. Nature Biotechnology, 2019, 37, 708-711.	17.5	24
27	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	3.8	19
28	Major Events in the Life Course of New Drugs, 2000â€“2016. New England Journal of Medicine, 2019, 380, e12.	27.0	9
29	Evaluating New Rules on Transparency in Cancer Research and Drug Development. JAMA Oncology, 2019, 5, 461.	7.1	3
30	Lifecycle Regulation of Artificial Intelligenceâ€“ and Machine Learningâ€“Based Software Devices in Medicine. JAMA - Journal of the American Medical Association, 2019, 322, 2285.	7.4	86
31	Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. JAMA Pediatrics, 2019, 173, 68.	6.2	36
32	Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. JAMA Internal Medicine, 2019, 179, 374.	5.1	18
33	Association between progressionâ€“free survival and patientsâ€™ quality of life in cancer clinical trials. International Journal of Cancer, 2019, 144, 1746-1751.	5.1	62
34	Clinical benefit and prices of cancer drugs in the United States and Europe.. Journal of Clinical Oncology, 2019, 37, 6638-6638.	1.6	1
35	Improving the Study of New Medicines for Children With Rare Diseases. JAMA Pediatrics, 2018, 172, 7.	6.2	6
36	Availability of paediatric information in European Medicines Agency approvals. The Lancet Child and Adolescent Health, 2018, 2, e9.	5.6	2

#	ARTICLE	IF	CITATIONS
37	Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007â€“2016. JNCI Cancer Spectrum, 2018, 2, pky016.	2.9	12
38	Efficacy, Safety, and Regulatory Approval of Food and Drug Administrationâ€“Designated Breakthrough and Nonbreakthrough Cancer Medicines. Journal of Clinical Oncology, 2018, 36, 1805-1812.	1.6	72
39	Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. Health Affairs, 2018, 37, 724-731.	5.2	27
40	Expansion of the Priority Review Voucher Program Under the 21 <sup>st</sup> Century Cures Act: Implications for Innovation and Public Health. American Journal of Law and Medicine, 2018, 44, 329-341.	0.2	0
41	Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.. Journal of Clinical Oncology, 2018, 36, 6573-6573.	1.6	2
42	Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. PLoS Medicine, 2018, 15, e1002520.	8.4	46
43	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health and Surveillance, 2018, 4, e1.	2.6	21
44	The Pediatric Research Equity Act Moves Into Adolescence. JAMA - Journal of the American Medical Association, 2017, 317, 259.	7.4	38
45	Ensuring Access to Injectable Generic Drugs â€” The Case of Intravesical BCG for Bladder Cancer. New England Journal of Medicine, 2017, 376, 1401-1403.	27.0	49
46	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. Clinical Pharmacology and Therapeutics, 2017, 102, 290-296.	4.7	11
47	Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. JAMA - Journal of the American Medical Association, 2017, 318, 388.	7.4	15
48	The FDAâ€™s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. JAMA - Journal of the American Medical Association, 2017, 318, 2137.	7.4	62
49	Public Participation in Drafting of the 21st Century Cures Act. Journal of Law, Medicine and Ethics, 2017, 45, 212-220.	0.9	0
50	Challenges in the Development of Novel Cardiovascular Therapies. Clinical Pharmacology and Therapeutics, 2017, 102, 194-196.	4.7	6
51	Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA - Journal of the American Medical Association, 2017, 318, 609.	7.4	28
52	Measuring the Value of New Medications and Implications for Medicareâ€™s Proposed Part B Drug Payment Model. JAMA Oncology, 2016, 2, 1125.	7.1	1
53	Public referendum on drug prices in the US: will it bring relief?. BMJ, The, 2016, 355, i5657.	6.0	7
54	Breakthrough Medical Devices and the 21st Century Cures Act. Annals of Internal Medicine, 2016, 164, 500.	3.9	11

#	ARTICLE	IF	CITATIONS
55	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. <i>JACC Basic To Translational Science</i> , 2016, 1, 301-308.	4.1	24
56	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. <i>JAMA Internal Medicine</i> , 2016, 176, 1826.	5.1	279
57	Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. <i>American Journal of Law and Medicine</i> , 2016, 42, 429-450.	0.2	4
58	Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. <i>BMJ, The</i> , 2016, 353, i3323.	6.0	66
59	Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies. <i>Health Affairs</i> , 2016, 35, 219-226.	5.2	9
60	Accelerating innovation in rapid diagnostics and targeted antibacterials. <i>Nature Biotechnology</i> , 2015, 33, 589-590.	17.5	8
61	Retinal Implants and Medicare Reimbursement Policies for Breakthrough Treatments in Ophthalmology. <i>JAMA Ophthalmology</i> , 2015, 133, 373.	2.5	2
62	Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012. <i>BMJ Open</i> , 2015, 5, e007987-e007987.	1.9	11
63	Survey of MD/MBA Programs. <i>Academic Medicine</i> , 2015, 90, 121.	1.6	18
64	Surgical Applications of 3-Dimensional Printing and Precision Medicine. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 305.	2.2	9
65	Precision medicine and the FDA's draft guidance on laboratory-developed tests. <i>Nature Biotechnology</i> , 2015, 33, 449-451.	17.5	9
66	Paying for innovation: Reimbursement incentives for antibiotics. <i>Science Translational Medicine</i> , 2015, 7, 276fs9.	12.4	11
67	Antimicrobial stewardship and public knowledge of antibiotics. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 1000-1001.	9.1	27
68	Two decades of new drug development for central nervous system disorders. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 815-816.	46.4	111
69	Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment. <i>PLoS Medicine</i> , 2014, 11, e1001738.	8.4	9
70	Drug Safety in the Digital Age. <i>New England Journal of Medicine</i> , 2014, 370, 2460-2462.	27.0	21
71	Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. <i>BMJ Open</i> , 2014, 4, e004143.	1.9	67
72	Quantifying The Food And Drug Administration's Rulemaking Delays Highlights The Need For Transparency. <i>Health Affairs</i> , 2014, 33, 309-315.	5.2	12

#	ARTICLE	IF	CITATIONS
73	Life Cycle of Medical Product Rules Issued by the US Food and Drug Administration. <i>Journal of Health Politics, Policy and Law</i> , 2014, 39, 751-780.	1.9	8
74	New Regulatory Paradigms for Innovative Drugs to Treat Pediatric Diseases. <i>JAMA Pediatrics</i> , 2014, 168, 879.	6.2	3
75	Association between fluoroquinolone resistance and resistance to other antimicrobial agents among <i>Escherichia coli</i> urinary isolates in the outpatient setting: a national cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1720-1722.	3.0	11
76	Target small firms for antibiotic innovation. <i>Science</i> , 2014, 344, 967-969.	12.6	15
77	Postmarketing Trials and Pediatric Device Approvals. <i>Pediatrics</i> , 2014, 133, e1197-e1202.	2.1	39
78	Assessment of US pathway for approving medical devices for rare conditions. <i>BMJ</i> , The, 2014, 348, g217-g217.	6.0	13
79	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies. <i>PLoS ONE</i> , 2013, 8, e71966.	2.5	23
80	Trends in Launch Prices and Price Increases for New Medicines for Urological Cancers. <i>Journal of Urology</i> , 0, , .	0.4	0